Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2016-01-01 DOI:10.2217/HEP.15.41

Josiah Cox, S. Weinman

引用次数: 116

Abstract

Hepatocellular carcinoma, one of the most common solid tumors worldwide, is poorly responsive to available chemotherapeutic approaches. While systemic chemotherapy is of limited benefit, intra-arterial delivery of doxorubicin to the tumor frequently produces tumor shrinkage. Its utility is limited, in part, by the frequent emergence of doxorubicin resistance. The mechanisms of this resistance include increased expression of multidrug resistance efflux pumps, alterations of the drug target, topoisomerase, and modulation of programmed cell death pathways. Many of these effects result from changes in miRNA expression and are particularly prominent in tumor cells with a stem cell phenotype. This review will summarize the current knowledge on the mechanisms of doxorubicin resistance of hepatocellular carcinoma and the potential for approaches toward therapeutic chemosensitization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝细胞癌中阿霉素耐药的机制。

肝细胞癌是世界上最常见的实体肿瘤之一，对现有的化疗方法反应较差。虽然全身化疗的益处有限，但动脉内给药多柔比星往往能使肿瘤缩小。它的效用有限，部分原因是阿霉素耐药性的频繁出现。这种耐药的机制包括多药耐药外排泵的表达增加、药物靶点、拓扑异构酶的改变和程序性细胞死亡途径的调节。许多这些影响是由miRNA表达的变化引起的，在具有干细胞表型的肿瘤细胞中尤为突出。本文将对肝细胞癌的阿霉素耐药机制和化疗增敏的潜在途径进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.